FDA posted a warning letter to a Clinical Investigator this week.
Dr. Khan was warned for failing to retain records, specifically:
- IP accountability
- Informed consents
- Case histories
FDA notes that the PI misunderstood the record retention requirements to be two years after the termination of the study at the site, as opposed to two years beyond the last marketing application.